

## TROMBÓLISE DIRIGIDA POR CATETER NA ISQUEMIA AGUDA DOS MEMBROS INFERIORES EM DIFERENTES ETIOLOGIAS

### CATHETER DIRECT THROMBOLYSIS IN ACUTE LOWER LIMB ISCHAEMIA IN DIFFERENT AETIOLOGIES

Tiago Soares<sup>1\*</sup>, Paulo Dias<sup>1</sup>, Sérgio Sampaio<sup>1</sup>, José Teixeira<sup>1</sup>

1. Serviço de Angiologia e Cirurgia Vascular; Centro Hospitalar Universitário de S. João, Porto, Portugal

Recebido em: 18/09/2021

Aceite para publicação em: 19/11/2021

### RESUMO

**Introdução:** Ao longo das últimas décadas houve uma evolução nas opções de tratamento da isquemia aguda de membro (IAM). Hoje em dia, a trombólise dirigida por cateter (TDC) é por vezes utilizada como alternativa à cirurgia no tratamento da IAM e pode oferecer algumas vantagens em relação à cirurgia convencional em pacientes devidamente seleccionados.

**Objectivo:** Avaliar os dados relativos à TDC para o tratamento da isquemia aguda de membro em diferentes etiologias.

**Materiais e métodos:** Foram consecutivamente analisados todos os pacientes submetidos a TDC na isquemia aguda de membro no nosso serviço de cirurgia vascular, entre 1 de Janeiro de 2011 e 31 de Agosto de 2017. Os resultados incluíram a patência primária aos 30 dias e um ano, complicações hemorrágicas, amputação *major* e mortalidade.

**Resultados:** No total foram incluídos 128 membros de 106 pacientes. O seguimento mediano foi de 14 meses [6–31 meses]. As etiologias de isquemia incluídas no estudo foram trombose de artérias nativas, trombose de *bypass* PTFE ou VGS, trombose intra-*stent*, trombose de aneurisma ou *entrapment* poplíteo e embolia arterial. De acordo com a classificação de *Rutherford* na IAM foram observados no grau I 12,5%, grau IIa 77,3% e grau IIb 10,2%. As taxas de patência primária foram de 72,8% e 47,8% a um e três anos, respectivamente. A reintervenção foi de 27,6% no grupo da trombose de artéria nativa, 65,2% no grupo da trombose de *bypass* de PTFE, e 18,2% no grupo da trombose intra-*stent*. Não foram verificadas reintervenções para os grupos de aneurisma poplíteo ou embolia arterial. A sobrevida livre de amputação foi de 83,3% aos 27 meses, e a incidência cumulativa de morte foi de 10,1% aos 32 meses. Observaram-se complicações em 40 procedimentos (31,3%); a maioria hemorragia *minor* do local de acesso e uma morte devido a acidente vascular cerebral hemorrágico.

**Conclusão:** A TDC embora associada a um risco acrescido de complicações hemorrágicas, é considerada um tratamento seguro e com resultados que podem reduzir a necessidade de tratamento cirúrgico convencional em doentes seleccionados. O nosso estudo vem reforçar o uso desta terapêutica como uma opção válida na IAM em diferentes etiologias.

### Palavras-chave

Catheter direct thrombolysis; Acute limb ischaemia

### ABSTRACT

**Introduction:** Over the past few decades management options of the acute limb ischaemia (ALI) have changed. Nowadays, catheter direct thrombolysis (CDT) is commonly used as an alternative to surgery in immediate management of the ALI and may offer certain advantages over surgery in appropriately selected patients.

---

\*Autor para correspondência.

Correio eletrónico: tiagojoasoares@hotmail.com (T. Soares).

**Objective:** To evaluate CDT data for the treatment of acute ischaemia in lower extremity in different aetiologies.

**Materials and methods:** All consecutive patients who underwent CDT for acute limb ischaemia in our vascular surgery department, between 1 January 2011 to 31 August 2017 were identified and reviewed. Outcome measures included primary patency at 30 days and one year, haemorrhagic complications, major amputation and mortality.

**Results:** In total, 128 limbs from 106 patients were included. The median follow-up was 14 months [range: 6–31 months]. The aetiologies of ischaemia included in the study were native artery thrombosis, PTFE and GSV bypass thrombosis, intra-stent thrombosis, popliteal aneurysm and entrapment thrombosis and arterial embolism. The Stages of ALI according to the Rutherford classification were 12,5% in class I, 77,3% in class IIa and 10,2% in class IIb. Primary patency rates were 71.3% and 47.8% at one and three years, respectively. The requirement for re-intervention was 27.6% in the native artery thrombosis group, 65.2% in the PTFE graft thrombosis group, and 18.2% in the intra-stent thrombosis group. No re-interventions were verified for popliteal aneurysm or arterial embolism aetiologies. The overall amputation free survival was 83.3% at 27 months, and the cumulative incidence of death was 10.1% at 32 months. Complications occurred in 40 interventions (31.3%); the majority comprised minor bleeding from the access site, and one death due to haemorrhagic stroke.

**Conclusions:** CDT although associated with an increased risk of bleeding complications, it is a feasible and safe therapy, with clinical outcomes that may reduce the need for open surgical treatment in many patients. Our findings support this therapeutic approach as a valid option in ALI, in different aetiologies.

#### Keywords

Catheter direct thrombolysis; Acute limb ischaemia

## INTRODUCTION

Traditionally, the treatment of ALI requires an open surgical intervention, and is associated with relatively high perioperative morbidity and mortality<sup>(1)</sup>. In recent decades, the use of catheter-directed thrombolysis (CDT) to treat ALI has become part of routine clinical care, primarily due to three large randomised controlled trials that demonstrated similar efficacies, when compared with open surgery<sup>(2–4)</sup>.

The CDT was introduced at our institution in 2011. The change in protocol occurred due to the discouraging results of surgical thrombectomy obtained in the same institution and published by the same author with a primary permeability at one year of 17.9% (PE = 6.5%), limb salvage rate at 1 month of 56.6% (PE = 6.9%) and at 4.5 years 40.3% (PE = 7.1)<sup>(5)</sup>.

Importantly, CDT facilitated the treatment of increased patient numbers, thus it was broadened to other aetiologies. Therefore, the aim of this paper is to present CDT data from our institute, in ALI for different aetiologies. We present these data using primary patency, amputation rate, complications and death as primary outcomes.

## MATERIAL AND METHODS

### Data Collection

This was a retrospective single centre analysis of electronic clinical data from consecutive patients with lower ALI, treated with CDT. All patients with acute occlusions below the abdominal aorta, undergoing thrombolysis between January 2011 and August 2017 were included.

### The CDT protocol

Preferential arterial access was via the common femoral artery. If not available, a brachial puncture was performed. A sheath was placed antero-grade or retrograde with low dose heparin infusion (500 U/h), and an intrathrombus straight catheter with multiple side holes, with a bolus of 1 mg alteplase and perfusion at a fixed dose of 0.5 mg/h. After procedure patients were admitted to an intermediate care unit under non-invasive monitoring. They had a daily angiography evaluation, with catheter adjustment based on angiographic findings, until technique success/failure was established, or interrupted due to complications.

**Statistics**

Data were analysed with IBM® SPSS Statistic, version 25. Univariate analyses of binary nominal and ordinal variables were conducted using cross-tabulations. T-tests for independent continuous variables and the Kaplan-Meier method were used to estimate primary permeability, mortality and death rates. Statistical significance was set at  $p < 0.05$ .

**Study definitions**

ALI was defined as relatively recent (< 15 days) onset or worsening of ischaemic manifestations of the lower extremities, divided by Rutherford classification (I, IIa, IIb and III).

Complications due to CDT included minor bleeding, defined as haematoma and bleeding from the access site. Major bleeding was defined where surgical intervention was required, i.e. gastrointestinal bleeding, cerebral haemorrhage or the blood transfusion of more than two units.

Adjuvant revascularisation was defined by the requirement for an additional procedure (endovascular or surgical) during the same hospital stay, when CDT was technically success. Success was defined as CDT that results in vessel patency, regardless of the need for adjuvant revascularisation.

Primary patency was defined as a vessel or graft that remained patent after the initial procedure

(with or without adjuvant revascularisation), and no additional intervention. Re-intervention was defined as occlusion in the same arterial segment that was previously thrombolysed. Major amputation was defined as amputation above the ankle joint.

**Results**

Between January 2011 and August 2017, 128 limbs were treated for ALI in 106 patients. Baseline demographics and comorbidities are shown (TABLE 1). The median follow-up time was 14 months [range: 6–31 months]. The mean age was 64.5 years [95% CI: 57–74], with mostly men ( $n = 108, 84.4\%, p < 0.01$ ) participating. Ischaemia aetiology include native artery thrombosis in 39 procedures (30.5%), PTFE graft thrombosis in 56 (43.8%), intra-stent thrombosis in 11 (8.6%), arterial embolism in nine (7%), popliteal aneurysm thrombosis in nine (7%), vein graft thrombosis in two (1.6%), and popliteal artery entrapment in two (1.6%). At presentation, 12.5% of patients had a viable extremity (Rutherford class I), 77.3% suffered a marginally threatened extremity (class IIa), 10.2% had an immediately threatening extremity (class IIb), and no patients showed irreversible ischaemia (class III). Adjuvant endovascular or open surgical procedures were common after thrombolysis (53.9%), with differences observed between all groups ( $p < 0.01$ ). All adjuvant procedures in the popliteal aneurysm group were performed by open surgery.

TABLE 1 Baseline demographics and characteristics.

Variable	Total	Native artery thrombosis	PTFE Bypass	GSV Bypass	Stent	Popliteal aneurysm	Arterial embolism	Popliteal Entrapment	pt
Nº procedures	128	39 (30,5%)	56(43,8%)	2 (1,6%)	11 (8,6%)	9 (7%)	9 (7%)	2 (1,6%)	
Age	64,5	64,8	63,7	76	63,8	62,3	71,1	46	0,021
Male	108 (84,4%)	31 (79,5%)	52 (92,9%)	2 (100%)	9 (81,8%)	9 (100%)	4 (44,4%)	1(50%)	<0,01
DM	33 (25,8%)	7 (17,9%)	19 (33,9%)	0	6 (54,5%)	0	1 (11,1%)	0	0,036
Smoking	89 (69,5%)	24 (61,5%)	45 (80,4%)	2 (100%)	8 (72,7%)	6 (66,7%)	2 (22,2%)	2 (100%)	0,016
Hypertension	86 (67,2%)	22 (56,4%)	41 (73,2%)	2 (100%)	8 (72,7%)	7 (77,8%)	6 (66,7%)	0	0,194
Dyslipidemia	73 (57%)	23 (18%)	31 (24,2%)	2 (100%)	8 (72,7%)	5 (55,6%)	4 (44,4%)	0	0,425
Renal disease	11 (8,6%)	3 (7,7%)	6 (10,7%)	0	0	1 (11,1%)	1 (11,1%)	0	0,927
Cerebrovascular disease	12 (9,4%)	1 (2,6%)	9 (16,1%)	0	1 (9,1%)	0	1 (11,1%)	0	0,373
Ischemic heart disease	37 (28,9%)	8 (20,5%)	19 (33,9%)	2 (100%)	4 (36,4%)	2 (22,2%)	2 (22,2%)	0	0,207

$p < 0.050$  versus other groups.

† Comparisons of all groups (cross tabulation with chi-square test for dichotomous variables and one way ANOVA for continuous variables).

TABLE 1 Baseline demographics and characteristics.

Variable	Total	Native artery thrombosis	PTFE Bypass	GSV Bypass	Stent	Popliteal aneurysm	Arterial embolism	Popliteal Entrapment	pt
Duration of symptoms (d)	5,72	6,8	5,2	9,5	3	3,78	8,67	5,5	0,25
Rutherford									<0,01
I	16 (12,5%)	5 (12,8%)	8 (14,3%)	0	1 (9,1%)	0	2 (22,2%)	0	
Ila	99 (77,3%)	33 (84,6%)	45 (80,4%)	2 (100%)	9 (81,8%)	5 (55,6%)	3 (33,3%)	2 (100%)	
Ilb	13 (10,2%)	1 (2,6%)	3 (5,4%)	0	1 (9,1%)	4 (44,4%)	4 (44,4%)	0	
Infra-inguinal occlusion	104 (81,9%)	29 (76,3%)	45 (80,4%)	2 (100%)	9 (81,8%)	9 (100%)	8 (88,9%)	2 (100%)	0,669

p < 0.050 versus other groups.

† Comparisons of all groups (cross tabulation with chi-square test for dichotomous variables and one way ANOVA for continuous variables).

Technical success was recorded in 106 procedures (82.8%), with no differences between groups. Complications occurred in 40 procedures (31.3%), in most cases due to minor bleeding (n = 31), but some cases were due to major bleeding (n = 6), and one death was recorded due to haemorrhagic stroke. The need to interrupt CDT due to haemorrhagic complication occurred in 17 procedures.

Primary outcomes are shown (TABLE 2). The overall primary patency rates were 89.7% and 71.3% at one month and one year, respectively, during which the stent group showed the poorest results: 47% at one year; whereas the popliteal aneurysm, arterial

embolism and popliteal entrapment groups had no recorded occlusions. The need for re-intervention when required, was performed in 27.6% in the native artery thrombosis group, 65.2% in the PTFE graft thrombosis group, and 18.2% in the intra-stent thrombosis group. No re-interventions were verified for popliteal aneurysm or arterial embolism aetiologies. Major amputations at one year occurred in 18 cases, with no differences between groups. No amputations were recorded in the great saphenous vein bypass, popliteal aneurysm, arterial embolism and entrapment popliteal groups.

TABLE 2 CDT outcomes

Variable	Total	Native artery thrombosis	PTFE Bypass	GSV Bypass	Stent	Popliteal aneurysm	Arterial embolism	Popliteal Entrapment	pt
Nº procedures	128	39 (30,5%)	56(43,8%)	2 (1,6%)	11 (8,6%)	9 (7%)	9 (7%)	2 (1,6%)	
Success	106 (82,8%)	34 (87,2%)	43 (76,8%)	2 (100%)	10 (90,9%)	7 (77,8%)	8 (88,9%)	2 (100%)	0,72
Adjuvant revascularization	69 (53,9%)	19 (48,7%)	26 (46,4%)	2 (100%)	7 (63,6%)	9 (100%)	5 (55,6%)	1 (50%)	<0,01
Endovascular	54 (42,2%)	17 (43,6%)	24 (42,9%)	2 (100%)	6 (54,5%)	0	5 (55,6%)	0	<0,01
Open	14 (10,9%)	2 (5,1%)	1 (1,8%)	0	1 (9,1%)	9 (100%)	0	1 (50%)	<0,01
Hybrid	1 (0,8%)	1 (1,8%)	0	0	0	0	0	0	
Complications	40 (31,3%)	7 (17,9%)	23 (41,1%)	0	5 (45,5%)	3 (33,3%)	2 (22,2%)	0	0,177
Minor bleeding	31 (24,2%)	6 (15,4%)	20 (35,7%)	0	4 (36,4%)	1 (11,1%)	0	0	0,072
Major bleeding	6 (4,7%)	1 (2,6%)	2 (3,6%)	0	0	2 (22,2%)	1 (11,1%)	0	0,216
Death	1 (0,8%)	0	0	0	1 (9,1%)	0	0	0	0,097

p < 0.050 versus other groups.

† Comparisons of all groups (cross tabulation with chi-square test for dichotomous variables and one way ANOVA for continuous variables).

TABLE 3 CDT outcomes

Variable	Total	Native artery thrombosis	PTFE Bypass	GSV Bypass	Stent	Popliteal aneurysm	Arterial embolism	Popliteal Entrapment
Primary Patency 30D	89,70%	97,40%	85,70%	100%	62,30%	100%	100%	100%
Primary Patency 1A	71,30%	90,70%	56,60%	100%	41,60%	100%	100%	100%
Major amputation 1A	10,80%	15,60%	16,20%	0	16,30%	11,10%	0	0
Death Follow-up	10,10%	13,70%	3,30%	0	14,30%	0	0	0

## DISCUSSION

This study demonstrated that in our institution, the treatment of ALI by CDT introduced a paradigm shift, and improved prognosis in these patients, when compared with previous institution data<sup>(5)</sup>. The study also presented an opportunity to investigate short and medium-term results for different subgroups, depending on the underlying cause of ALI. Our improvements were reflected by primary patency rates, amputation rates and number of deaths.

The primary success was 82.8%, similar to previous studies<sup>(6-8)</sup>, and the poorest results were observed in the PTFE bypass group, with a success rate of 76.8%. The overall primary patency rates at one month and one year were 89.7% and 71.3%, respectively, with the poorest results in the stent group (62.3% and 41.6% at one month and one year, respectively). This observation may result from progression disease with no adjuvant revascularisation in remaining residual lesions in the end of CDT.

A known and accepted disadvantage of thrombolysis is the increased risk of haemorrhagic complications<sup>(9,10)</sup>. In this study, our complication numbers were similar to previous studies<sup>(11, 12)</sup>, with an overall incidence rate of 31%. However, most reported bleeding was minor (24.2%), with a major bleeding incidence rate observed in only 4.7% of procedures. One death was recorded for haemorrhagic stroke (0.8%). These results corresponded to a lower incidence of serious bleeding complications, when compared to previous studies<sup>(13, 14)</sup>. This low rate may be explained by strict patient surveillance in intermediate care units, and an immediate cessation or dose decrease in thrombolytic when bleeding was observed. Our rate of amputation at one year was 10.8%, similar to a previous study<sup>(15)</sup>. Our study had some limitations. Firstly, it was retrospective in nature, and therefore had all the limitations associated with this study design. However, in mitigation, it included all consecutive cases in

the study period. Secondly, the distinction between thrombotic and embolic occlusion, based on imaging findings are sometimes difficult, which may have led to imprecise classification. Nevertheless for all doubtful cases, two or more opinions were required to agree on aetiology.

## CONCLUSIONS

CDT achieved good short and mid-term clinical outcomes, reducing the need for open surgical treatment in many patients. These data support CDT as a valid option for ALI, with several aetiologies.

## REFERENCES

1. Jivegard, L., J. Holm, and T. Schersten, Acute limb ischemia due to arterial embolism or thrombosis: influence of limb ischemia versus pre-existing cardiac disease on postoperative mortality rate. *J Cardiovasc Surg (Torino)*, 1988. 29(1): p. 32-6.
2. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. *Ann Surg*, 1994. 220(3): p. 251-66; discussion 266-8.
3. Ouriel, K., et al., A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. *J Vasc Surg*, 1994. 19(6): p. 1021-30.
4. Ouriel, K., F.J. Veith, and A.A. Sasahara, A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. *Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med*, 1998. 338(16): p. 1105-11.
5. De Carvalho, J.S., S. Roncon, R., Occlusion of prosthetic bypass. Experience of five consecutive years. *Rev Port Cir Cardiorac Vasc*, 2013. 20(2): 93-7.
6. Kashyap, V.S., et al., Endovascular therapy for acute limb ischemia. *J Vasc Surg*, 2011. 53(2): p. 340-6.
7. Lokse Nilssen, G.A., et al., Results of catheter-directed endovascular thrombolytic treatment of acute ischaemia of the leg. *Eur J Vasc Endovasc Surg*, 2011. 41(1): p. 91-6.

8. Robertson, I., D.O. Kessel, and D.C. Berridge, *Fibrinolytic agents for peripheral arterial occlusion. Cochrane Database Syst Rev*, 2013(12): p. CD001099.
9. Theodoridis, P.G., et al., *Thrombolysis in Acute Lower Limb Ischemia: Review of the Current Literature. Ann Vasc Surg*, 2018. 52: p. 255-262.
10. Ebben, H.P., et al., *Catheter Directed Thrombolysis Protocols for Peripheral Arterial Occlusions: a Systematic Review. Eur J Vasc Endovasc Surg*, 2019. 57(5): p. 667-675.
11. Kuoppala, M., J. Akesson, and S. Acosta, *Outcome after thrombolysis for occluded endoprosthesis, bypasses and native arteries in patients with lower limb ischemia. Thromb Res*, 2014. 134(1): p. 23-8.
12. Grip, O., et al., *Long-term Outcome after Thrombolysis for Acute Lower Limb Ischaemia. Eur J Vasc Endovasc Surg*, 2017. 53(6): p. 853-861.
13. Darwood, R., et al., *Surgery versus thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev*, 2018. 8: p. CD002784.
14. Veenstra, E.B., et al., *A systematic review and meta-analysis of endovascular and surgical revascularization techniques in acute limb ischemia. J Vasc Surg*, 2020. 71(2): p. 654-668 e3.
15. Urbak, L., et al., *Catheter-Directed Thrombolysis in the Treatment of Acute Ischemia in Lower Extremities Is Safe and Effective, Especially with Concomitant Endovascular Treatment. Ann Vasc Dis*, 2017. 10(2): p. 125-131.